Fig. 8

In vitro, the YAP inhibitor VP reverses the regulatory effect of Gap19 on the Cx43-YAP-SOCS axis. a, b At the beginning of hemin stimulation, astrocytes were treated with the YAP inhibitor VP. WB analysis showed that VP suppressed the increase in SOCS1/SOCS3 levels induced by Gap19 treatment. c, d Representative photos showing the levels of TLR4, p-IKKβ, IKKβ, IKBα, p65, p-p65, and β-tubulin after treatment with the YAP inhibitor VP. e, f Representative photographs showing the levels of JAK2, p-JAK2, STAT3, p-STAT3, and β-tubulin after treatment with the YAP inhibitor VP. g qRT-PCR analysis of the transcriptional activities of IL-1β, IL-6, TNF-α, and MCP1 in astrocytes after VP treatment. The bars represent the SEM of the data from 3 samples per group. *P < 0.05, **P < 0.01 compared to the hemin group. #P < 0.05, ##P < 0.01 compared with the Gap19 + hemin group